

Disclosures – a2 Milk Company Funding/Consultancies

Introduction

1. **Prof Keith Woodford** (Lincoln University, NZ). Acted as a scientific consultant to A2 Corporation in 2013, for several months. Woodford has not received any funding since. He worked as a researcher on Ass. Prof Sebely Pal's project, without any a2 funding.
 2. **Prof Boyd Swinburn** (Auckland University, NZ). Has never received any a2 Milk Company (a2MC) funding for research or consulting. He wrote the NZFSA report on beta-casein and human health in 2004.
-

Session 2: Current Research – Gut Health

1. **Prof Peter Gibson** (Monash University, VIC). Is currently receiving a2MC funding to conduct an A1 vs A2 beta-casein in milk study in patients with IBS – see details <http://www.med.monash.edu/cecs/gastro/clin-trials/ct-a2milk.html>. However, the study is being run completely independently of the a2MC.
 2. **Assoc Prof Sebely Pal** (Curtin University, WA). Received funding from the a2MC to conduct a human intervention study. Keith Woodford was not acting on behalf of the a2MC nor was he paid by the a2MC for his role as an investigator on this study.
 3. **Dr Sue McGlashan** (Auckland University, NZ). Research has not been funded by the dairy industry or the a2MC. Funding has been from internal University funds and Curekids (NZ).
-

Session 3: Current Research – Infant Health & Diabetes

1. **Dr Ashwantha Enjapoori** (Deakin University, VIC). Received funding from the a2MC and is also receiving Australian government funding on this project - part of the Innovation Connections (IC) program. Dr Enjapoori has worked on mass spectrometry techniques for identification of human and bovine beta-casomorphins in breast milk and other biological fluids. He has submitted a paper for publication on this topic.
 2. **Prof Karen Dwyer** (Deakin University, VIC). Received funding from the a2MC as well as institutional funding for her research on A1 beta-casein and type 1 diabetes in mice.
 3. **Prof John Carver** (ANU, CANBERRA). Has never received any funding from the a2MC for research or consulting.
-

Session 4: Clinical Implications and the Gaps in the Research

1. **Dr Robert Loblay** (Royal Prince Alfred Hospital, Sydney). Has never received funding from the a2MC for research or consulting. Robert is an academic and clinical immunologist at The Royal Prince Alfred Hospital. Robert has conducted research in the Autistic Spectrum Disorder (ASD) and exorphin area. Rob's group have looked at the wheat/milk issue (exorphins derived from gluten/casein) in the past, but were not able to confirm previously published findings.
– <http://www.sswahs.nsw.gov.au/rpa/allergy/research/students/2005/AngieLow.pdf>
– <http://www.sswahs.nsw.gov.au/rpa/allergy/research/students/2003/KarynMatterson.pdf>
 2. **Prof Andrew Sinclair** (Deakin University, VIC). Has never received any funding from the a2MC for research or consulting.
-

Travel Grants to Attend the Workshop

The following presenter in this workshop had their airfares and accommodation (as needed) paid for by funding from the a2MC (Australia) Pty Ltd:

- Professor John Carver
- Dr Robert Loblay
- Honorary Professor Keith Woodford
- Associate Professor Sebely Pal
- Professor Boyd Swinburn
- Dr Sue McGlashan
- Professor Andrew Sinclair
- Dr Ashwantha Enjapoori
- Professor Karen Dwyer